1. Home
  2. MOGO vs AKTX Comparison

MOGO vs AKTX Comparison

Compare MOGO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mogo Inc.

MOGO

Mogo Inc.

HOLD

Current Price

$1.10

Market Cap

27.6M

Sector

N/A

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.39

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOGO
AKTX
Founded
2003
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.6M
14.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MOGO
AKTX
Price
$1.10
$0.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.00
$3.30
AVG Volume (30 Days)
116.8K
1.4M
Earning Date
11-07-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.22
N/A
Revenue
$29,215,516.00
N/A
Revenue This Year
$63.05
N/A
Revenue Next Year
$5.58
N/A
P/E Ratio
$5.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.26
52 Week High
$3.83
$1.73

Technical Indicators

Market Signals
Indicator
MOGO
AKTX
Relative Strength Index (RSI) 31.65 39.04
Support Level $1.14 $0.26
Resistance Level $1.22 $0.47
Average True Range (ATR) 0.06 0.07
MACD 0.01 0.01
Stochastic Oscillator 0.00 38.34

Price Performance

Historical Comparison
MOGO
AKTX

About MOGO Mogo Inc.

Mogo Inc is a Canadian-based financial technology company. It offers a finance application to consumers with solutions that help them to control their financial health. At Mogo, users can sign up for a free account and get access to products and solutions that help users to monitor their credit score, protect themselves from identity fraud, control their spending, and borrow responsibly. Company offers digital loans and mortgages and also offer a digital payments platform that powers next-generation card programs for both established world-wide corporations and fintech companies in Europe and Canada.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: